Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study investigates brain effects of CAR T-Cell therapy in young cancer patients

NCT ID NCT05237986

Knowledge-focused Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Sep 01, 2026 · Updated 20 times

Summary

This study looks at how CAR T-cell therapy, a treatment for blood cancers, might affect thinking and memory in children and young adults aged 5 to 35. Researchers will test participants' memory, attention, and other thinking skills before and after treatment, over up to 3 years. The goal is to understand any brain-related side effects and help improve care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
CAR T-cell therapy
What this could lead to
If successful, this study could help doctors understand and manage any thinking or memory changes that may occur after CAR T-cell therapy.
What could go wrong
This is an observational study, not a treatment trial. It only measures effects, so it won't directly improve outcomes. Results may take years and might not lead to changes in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

A government research agency

The lead sponsor is the US National Institutes of Health.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants with relapsed/refractory leukemias or lymphomas, scheduled to receive CAR T-cell therapy and their caregiver(s).

Ages

5 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

* INCLUSION CRITERIA: * Participants with disease * Participants are diagnosed with relapsed/refractory leukemias or lymphomas, and are scheduled to receive CAR T-cell treatment in one of the enrolling sites * For participants enrolled on a CAR T-cell treatment protocol, data sharing for the purposes of this study must be allowed. * Age \>= 5 and \<=35 years old * Participant must have an eligible caregiver (informant) who is willing to complete assessments about the participant of this study * Participants (\<18 years, or \>=18 years if needed) must have an eligible caregiver to assist with setting up an appropriate test environment for the remote evaluations * Participant must be able to speak and understand English or Spanish * Participants must have access to a computer or tablet with a camera and an internet connection * Participant or parent/guardian must be able to understand and willing to sign a written consent document * Caregivers (informants) * Participants must be able to speak and read in English or Spanish * Participants who are caregivers for participants with disease addressed above * Age \>= 18 years old * Participants must have access to a computer or tablet * Participants (of children \<18 years, or \>18 years if needed) must be willing to help set up an appropriate test environment for the remote evaluations * Participant is able to understand and willing to sign a written consent document EXCLUSION CRITERIA: -Participants with disease who have a pre-existing global intellectual disability (e.g., Down Syndrome)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Leukemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

leukemia lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Leukemia Lymphoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Children s Hospital of Los Angeles

    RECRUITING

    Los Angeles, California, 90027, United States

  • National Institutes of Health Clinical Center

    RECRUITING

    Bethesda, Maryland, 20892, United States

  • Seattle Children s Hospital

    RECRUITING

    Seattle, Washington, 98105, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.